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CLEAR CELL SARCOMA- a review  
 
Abstract:  
Clear cell sarcoma (CCS) previously known as malignnt melanoma (MM) of the soft tissue, 
although, similar in morphology to MM, contemporary histopathologic and cytogenetic techniques 
have made this diagnosis obsolete, as it is now possible to distinguish between CCS and MM. CCS 
is often diagnosed in young adults with median age of 25 years. Overall mortality is generally poor, 
and the 5-year survival is between 40 - 60 %. Hence, early diagnosis and radical surgery are key in 
the treatment of this extremely rare malignancy of the soft tissue comprising only about 1 % of all 
sarcomas. This article present an overview of this rare malignancy.  
Keywords: sarcoma; clear cell sarcoma; malignant melanoma of the soft tissue; treatment of clear 
cell sarcoma  
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Introduction 
Clear cell sarcoma (CCS) is an extremely rare and aggressive subtype of sarcoma with melanocytic 
differentiation both immunohistochemically, ultrastructural and genomic 1,2. It comprises 
approximately 1 % of all diagnosed sarcomas 3. Furthermore, the prognosis is poor due to 
predilection for metastasis at an early stage to the lymphatic system and the lungs 4. CCS is thought 
to derive from the neural crest cells 5. As a whole, sarcomas arises from the mesenchymal tissues, 
such as bone, muscle, fat, connective tissue, blood vessels and nerves5. Hence, corresponding tissue 
origin of clear cell sarcoma, which was first described by Enzinger et al in 1965 6. The name CCS 
originates from the initial histopathological findigs of clear cells, as the cytoplasm of the tumor 
cells may appear clear 6. The term malignant melanoma of the soft tissue was previously used, 
however, contemporary histopathologic and cytogenetic techniques have made this diagnosis 
obsolete, as pathologist are able to distinguish between CCS and malignant melanoma today 7. In 95 
% of the cases, the CCS arises in the lower extremities, particularly the foot and ankle. It presents as 
an indolent, growing and painless mass situated in the deep soft tissue or beneath the fascia 4,8–10. 
CCS occur at all ages, but is most often observed in the third decade 11–14. The mean age at the time 
of diagnosis is approximately 25 years and CCS is more common in Caucasians than in African 
Americans or Asians, without any gender predilection11–14. The aetiology of CCS is virtually 
unknown, and the exact cause and the mechanisms of formation remains to be elucidated. Genetic 
defects occurring on account of certain chromosomal exchanges is thought to play a key role in the 
formation. Hence, CCS is repeatedly seen in relation to specific genetic transformations. Only a few 
known risk factors are described .g. exposure to chemicals (vinyl chloride, arsenic), chronic tissue 
irritation (lymphedema, foreign body implants) and ra iation 5. 
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Diagnosis  
Compared to the aforementioned, identifying and diagnosing CCS is challenging. Quick and 
accurate diagnosis is dependent on the level of experience of the doctor at the initial examination 
and fast referral to specialized units with relevant experience, such as tertiary sarcoma centres are 
imperative. The mean time from onset of symptoms to confirmation of the diagnosis is often several 
months, which could be the result of an initial suspicion of a benign tumor 13,14. This prolonged time 
to relevant examinations and to diagnosis may lead to a more advanced disease at the time of 
diagnosis and therefore a more sinister prognosis 5,14,15.  
 
Radiological examination 
Hitherto, the most relevant initial investigation i the diagnosis of CCS is magnetic resonance 
imaging (MRI). Currently, no exact radiological crite ia to differentiate between malignant and 
benign tumors in the soft tissue exist 7,16–18. However, today a combination of different imaging 
tools is used to provide a tentative diagnosis, while t e final diagnosis of CCS is made, based on the 
resulting or concomitant pathological examination.  
 MRI is the leading and most established modality to identify the primary tumor and its 
relations to adjacent structures 17.  In addition, conventional ultrasound and computed tomography 
(CT) may be utilized as supplements and primary investigation in the few cases of contraindications 
to the MRI or because these modalities are more widly available.  
 When diagnosing CCS, it is important to consider obtaining the best possible preoperative 
imaging simultaneously, as surgery is the primary and possible curative treatment and further 
delays in terms of planning radical surgery, may render the prognosis even worse. As such the MRI 
produces a clear image of the tumor, and its relations to local structures e.g. nerves and major blood 
vessels, which may result in reduced per operative morbidity due to better planning (Figure 1). 
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***** Figure 1 near here ***** 
 
As CCS typically disseminate by haematogenous spread to the lungs or via the lymphatic system, 
Positron emission tomography–computed tomography (PET-CT) scan may be used to evaluate 
patients’ status in terms of radical surgery.  
Pathological examination 
The final diagnosis of CCS is pathological. Macroscopi ally the CCS appears to be well-defined 
solid tumors, with mat grey color that frequently infiltrate tendons and aponeuroses. 
Microscopically findings are small compact nests with uniform neoplastic cells divided into 
variable sized clusters by fibrous septa along the tendons and aponeuroses 2,6. The tumor cells 
typically appear with a clear eosinophilic cytoplasm and a basophilic nucleolus (Figure 2). The 
eosinophilic cytoplasm is due to the accumulation of glycogen, which can be visualized using 
periodic (PAS) stain method. The tumor cells show none or a minimal rate of mitosis in 
concordance with the slow growth rate of CCS. Scattered giant cells with 10-16 nucleoli and 
scattered necrosis may also be identified in CCS 2.      
 
***** Figure 2 near here ***** 
 
Immunohistochemical studies of CCS show great similarity to the characteristics of malignant 
melanoma, including a strong expression of S-100, HMB-45, Melan-A and microphthalmia-
associated transcription factor (MITF) in 81-97 % of the cases 2,19. Clear cell sarcoma is associated 
the chromosomal fusion of the Ewing’s Sarcoma oncogene (EWS) and the cellular transcription 
factor (ATF1) into EWS/ATF1 oncogene 20. This chromosomal fusion due to (t[12; 22] [q13; q12]) 
can be detected with cytogenetic investigations, e.g. polymerase chain reaction (PCR) and 
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fluorescence in situ hybridization (FISH) in 90% ofthe cases 20. In addition, to the before 
mentioned translocation, a fusion between Ewing Sarcoma Breakpoint Region 1(EWSR1) and 
Camp Responsive Element Binding Protein 1 (CREB1) is also known to give rise to CCS 21.  
Studies have shown that EWSR1/ATFI fusion protein is able to bind and activate melanocyte 
specific MITF via SRY-related HMG-box 10 (SOX10) transcription factor, which results in the 
expression of the melanocytic phenotype, thus the malignant melanoma is a differential diagnosis 
22,23.    
 
Differential diagnosis 
The diagnosis of CCS may be difficult and differential diagnosis are plenty and include melanoma, 
epithelioid malignant peripheral nerve sheath tumor, cellular blue naevus, melanotic schwannoma, 
paraganglioma-like dermal melanocytic tumor, synovial sarcoma (monophasic type), 
paraganglioma, epithelioid sarcoma and carcinomas24. In comparison to melanoma although 
clinically distinctive, the initial pathological examination may be ambiguous, hence bear in mind 
that CCS is more deeply located, in close relation to tendons or aponeuroses and with no epidermal 
involvement. In contrast, a primary cutaneous nodular melanoma is usually situated in the dermis 
and tends to be more pleomorphic and enlarging more rapidly than CCS. Remember that melanoma 
metastasis can be found in deeper tissue (Figure 1). Melanotic schwannoma are rare and most often 
occurs in patients with Carney syndrome, together with spotty skin and myxomas. These 
schwannomas are situated in paraspinal or nerve plexus-related locations and frequently contains 
calcifications and very abundant melanin pigment 24. 
Malignant peripheral nerve sheath tumor is, as indicated in the name, associated with a large 
peripheral nerve or neurofibromatosis and is histologically characterized by significant myxoid 
stroma (i.e. pale to light basophilic stroma) in haematoxylin and eosin stains, hyperchromatic 
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nuclei, brisk mitotic activity, negativity for HMB-45, melanocytic markers and cytogenetic 
abnormalities 3. In contrast to CCS, paraganglioma-like dermal melanocytic tumor is a tumor of the 
extremities of only females, which presents as a dermal nodule with distinct histological 
appearance, large epithelioid cells with distinct large nuclei, prominent nucleoli and absence of 
genomic EWS rearrangement. 
 
Treatment 
Margin-free surgery is the primary treatment of CCS 8,9,18,25. Recommendations are surgical 
excision with a sufficient amount of surrounding healthy tissue. Most authors recommend a margin 
of one centimetre or more, although this is a matter of ongoing debate 8,9,15. Adjuvant treatment as 
discussed below is recommended in cases, where it is not possible to meet the recommendations of 
margins 26. Amputation following CCS is rarely used in contemporary medicine 15. One third of 
patients if undergoing sentinel node procedure or subsequently lymph node dissection present with 
lymphatic metastasis and these procedures are discussed in regards of locoregional disease control 
8. The procedures seem to predict recurrent disease as well as survival but are not yet widely 
implemented.  
 
Radiation therapy 
Adjuvant radiation therapy can be used as a postoperativ  adjuvant treatment of CCS 27. It is 
commonly used in delicate situations, where the recommended margin of one centimetre of healthy 
tissue cannot be achieved and additional surgery is not feasible or refused by the patient 18,28,29.  
It is unclear whether adjuvant radiotherapy has a beneficial effect on survival 27. It is recommended 
in cases of high grade (grade 2–3) and large (>5 centim tres) soft tissue sarcomas (level IIB) 30. 
Grading are enumerated in Figure 3. 
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***** Figure 3 near here ***** 
Clear cell sarcoma, however, typically has low mitotic activity and necrosis is only seen 
occasionally in these tumors, classifying most CCSs as grade 1 tumors 29. In cases with negative 
surgical margins, a radiation dosis of 50 Gy is recommended in fractions of 1.8 to 2.0 Gy. If 
positive margins are present a postoperative radiation regime of 60-66 Gy is recommended29. 
Chemotherapy 
If complete excision with sufficient margin is achieved, adjuvant treatments are not necessary 26. 
Chemotherapy is indicated in patients with metastatic disease but the efficiency still remains 
unclear, although it is being used as palliative treatment 25,26,31. Hence, in a retrospective study of 24 
patients, investigating the response rate of metastatic CCS disease and the treatment with 
chemotherapy the authors found that treatment with an racycline based chemotherapy was the only 
therapy with partial effect on metastatic CCS, as the response rate was 4 % 13. Both cisplatin and 
ifosamide based protocols only managed stable disease in two patients with a progression free 
period of 11 weeks 13. Similar findings, in another study in which advanced CCS disease was 
studied in 11 patients with a combination of doxorubicin, dacarbazine and ifosfamide, as only two 
patients achieved partial response or stable disease and it lasted less than six months 32.  
 
Postoperative control 
An extensive follow-up program is advised and instituted in most countries, due to the high risk of 
metastases and relapse. The purpose is to exclude recurrence and metastases, in addition to address 
occupational health issues, practical needs, and to support self-care and negate long-term sequelae 
of the treatment. 
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 The following is recommended. Histopathological low grade tumors (grade 1) are to be 
followed once every three months the first year, once every four months for two-three years and 
hereafter twice a year until the fifth postoperative year 33. Clinical monitoring is especially 
important when it comes to local recurrence and clinical examination should be supplemented with 
MRI on any suspicion34. Patients with high grade tumors (grades 2-3) are recommended to follow a 
rigid scheme of controls every three months for the first three years and then twice a year through 
the fifth year 33. Even with a negative clinical examination, it is still recommended to have regular 
MRI of previous tumor site twice a year. The exact role of PET-CT and chest x-ray is not fully 
established but often used on suspicion in order to exclude metastases 35. Individualized control 
programs can occur in up to ten years postoperatively. Patients that have received chemotherapy 
should also be examined biochemically with liver, kidney, and heart function parameters because of 
the risk of side-effects.   
 
Prognosis 
The prognosis of CCS is poor because of the tendency to metastasize at an early disease-state and 
due to the rate of recurrence 8,15,18. Local recurrence rate may be as high as 84 % and 30 % of 
patients have metastases at the time of diagnosis 7,15,36. Negatively associated prognostic factors are 
necrosis, the number of mitosis, resection margin, anatomic location and tumor size 11,15,26. Tumor 
size, at the time of surgery, seems to be the key factor and is most strongly correlated to survival. 
Tumors larger than five centimetres are proven to recur more often because of micro metastasis 
11,19,25.  
Conclusion 
CCS is a rare malignant disease with very low incidence of the soft tissue with numerous 
differential diagnoses. The incidence is very low and the prognosis is poor. Primary treatment is 
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radical surgical extirpation and an extensive postoperative follow-up program. The role of adjuvant 
therapy i.e. radiation and chemotherapy remains to be elucidated nd larger prospective studies are 
required to establish the optimal treatment.   
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Figure 1: 
MRI scan: An 80-year-old woman with subcutaneous soft tissue tumor in the lower extremities 
with relation to both tendons, skin and vital blood vessels. Primary differential diagnosis was 
sarcoma. A biopsy was performed. Histopathological ex minations raised doubt regarding the 
diagnosis; was it malignant melanoma or clear cell sarcoma. Subsequently verified as a metastasis 
of malignant melanoma.  
 
Figure 2 
CCS, hematoxylin-eosin stain: There are irregular nests of cells separated by fibrous septa. Cells 
are fusiform and not pleomorphic. They have regular vesicular nuclei and prominent nucleoli with 
moderate to abundant eosinophilic or clear cytoplasm.  
Figure 3:  
FNCLCC grading  
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Figure 1 
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Figure 2:  
 
 
 
Figure 3:  
 
